OPKO Health, Inc. Provides Earnings Guidance for the Third Quarter of 2021
July 30, 2021 at 02:00 am IST
Share
OPKO Health, Inc. provided earnings guidance for the third quarter of 2021. The company expects revenue for the third quarter of 2021 to be between 270 million and $300 million, including revenue from services of $230 million to $270 million. Forecasted operating income includes a gain of approximately $30 million resulting from the disposition of EriGen facility. Operating profit also includes approximately $20 million of noncash depreciation and amortization expense as well as expected investment in research and development of $18 million to $22 million.
OPKO Health, Inc. is a multinational biopharmaceutical and diagnostics company. The Company's diagnostics segment consists of the clinical laboratory operations of BioReference Health, LLC (BioReference), its point-of-care operations. Its pharmaceutical segment consists of the pharmaceutical operations in Chile, Mexico, Ireland, Israel, Spain, Ecuador, France, the United States, and its pharmaceutical research and development operations. Through BioReference, it operates specialized laboratory divisions, such as GenPath (Urology), GenPath (Oncology), and GenPath (Women's Health). It has two commercial stage pharmaceutical products and several pharmaceutical compounds and technologies in various stages of research and development for a range of indications and conditions, including Rayaldee, Rayaldee, Oxyntomodulin, Biologics, NGENLA Somatrogon, and Factor VIIa-CTP. It develops and manufactures specialty active pharmaceutical ingredients (APIs) through FineTech Pharmaceutical, Ltd.
OPKO HEALTH, INC. 
